American Cyanamid Company is a leading global developer and marketer of crop protection products for agricultural and specialty markets. Cyanamid produces and markets herbicides, insecticides and fungicides in the major agricultural regions of the world. It was the first to introduce herbicide tolerant cropping systems, based on its proprietary imidazolinone chemistry. Cyanamid's CLEARFIELD* Production System combines herbicide tolerant crops with custom designed herbicide solutions. American Cyanamid is a subsidiary of American Home Products (NYSE: AHP). On March 21, 2000 AHP announced that it had entered into an agreement with BASF Aktiengesellschaft (NYSE: BF) to acquire AHP's Cyanamid Agricultural Products business, pending approval by government antitrust authorities.
Fuso Pharmaceutical Industries, Ltd. is a Japan-based company principally involved in the manufacture and sale of pharmaceuticals and medical equipment. Along with its subsidiary, Fuso Pharmaceutical operates in two business segments. The Pharmaceuticals segment manufactures and sells pharmaceutical products, such as dialysates for artificial kidneys and injection solutions that include infusion solutions, as well as medical equipment and instruments. The Estate segment specializes in the leasing of real estate properties. The Company has one subsidiary. (Source: ARS)
Corium International, Inc. is a privately-owned company engaged in the research, development and manufacture of advanced transdermal drug delivery technologies and products. Using its proprietary delivery technologies and its development and manufacturing expertise, Corium has developed a number of active and passive transdermal products with enhanced therapeutic or safety profiles. This self-funded product pipeline spans several therapeutic areas and is in various stages of development. Corium also has several partner-funded products with small, medium and large pharmaceutical companies in various stages of development, ranging from manufacturing to research and development.
http://www.leepharmaceuticals.com
Lee Pharmaceuticals is an established manufacturer of quality lip balm, saline nasal spray and OTC products. We are aggressively pursuing the Private Label Lip Balm and OTC business with our products that are national brand equivalent. Lee Pharmaceuticals has expanded its plant capacity and is prime on a full offering of personal health items. All private label items are qualified as national brand equivalent. Lee Pharmaceuticals has the resources, the ability, and the capability to produce art work and finished quality product with your brand name and logo.
http://www.trilliumhealthcare.com
Trillium operates two manufacturing facilities, a cGMP pharmaceutical facility and a highly efficient bar soap plant, both strategically located in North America. Our manufacturing capabilities include oral liquids, topicals & skin cleansers, suppositories, oral solid dose, and bar soap, and encompass a wide range of markets in personal care, health and wellness, and prescription medicine. Trillium's quality assurance and validation programs ensure that all of our manufacturing and testing practices meet the highest international standards of health product manufacturing, positioning Trillium as a global supplier to the industry. Our experienced management and employees are committed to excellence in all of our operations, processes and facilities; a commitment that has earned Trillium a strong reputation with our customers, who count on us to supply their important products. High quality, outstanding service and exceptional flexibility are the foundation of Trillium's mission to be North America's top performing contract manufacturer of health and personal care products for the pharmaceutical and consumer healthcare industries.
Orbus Pharma Inc. (Orbus) is a generic drug development and manufacturing company. The generic products developed by the Company are the therapeutic equivalent to their brand name counterparts. Orbus targets and develops generic versions of certain brand name products to license to sales and marketing licensee organizations. The Company is dependent on these licensees to sell and distribute the Orbus products in their respective markets under their own name. Orbus has targeted Europe, Canada and the United States as its primary markets. Orbus has two licensed certified good manufacturing practice (cGMP) manufacturing plants: a 10,000-square-foot antibiotics manufacturing plant located at 221 Shearson Crescent in Cambridge, Ontario, and a 21,000-square-foot oral dose manufacturing and development site located at 20 Konrad Crescent in Markham, Ontario. (Source: ARS)
We are the world leader in DNA repair technology and its application to skin care. We are also the world's foremost liposome manufacturer for skincare. Our ideas get transformed into products used by millions across the globe. Our business was founded as a classic, one-man bootstrap operation in 1985. Circa 2006, we have a staff of 30. Early on, our focus was applications of DNA repair technology. Today, we are dedicated to developing the next wave of medications and treatment products for the skin, based on DNA science.
BioSpecifics Technologies Corp. is a biopharmaceutical company that has been involved in the development of injectable collagenase (XIAFLEX) for multiple indications. The indications are for the treatment of Dupuytren’s disease, Peyronie’s disease and frozen shoulder. The Company has a development and license agreement with Auxilium Pharmaceuticals, Inc. (Auxilium) for XIAFLEX. Under this agreement, BioSpecifics Technologies has granted Auxilium a worldwide license to develop products containing XIAFLEX and the option to develop and license the technology for use in additional indications other than dermal formulations labeled for topical administration, including cellulite and lipomas. XIAFLEX is in a Phase III trial for treatment of Dupuytren’s disease. (Source: 10KSB)
instaCare is developing products that offer unique solutions in medical care and management by providing physicians with essential information at the point of care. Unlike other medical information systems using standard computer terminals, instaCare uses palm-sized computers (PDA's), which allow physicians to carry, access and update their patients' histories, medication data, and best care guidelines - all at the point of care. instaCare has established a core management team experienced in all phases of health care, data management and the Web.
Rosemont Pharmaceuticals Ltd. is a leading developer, manufacturer and supplier of high quality oral liquid medicines which are used by patients who are unable or unwilling to swallow solid medications. We are based in Leeds, West Yorkshire in the UK, and employ approximately 170 people. Through our significant R&D expertise, we have developed over 90 oral liquid medicines, and our customers see us as 'The Source of Liquid Solutions'.
http://www.manhattanpharma.com
Manhattan Pharmaceuticals, Inc. is a clinical-stage specialty pharmaceutical company focused on developing and commercializing pharmaceutical therapies for underserved patient populations. The Company has four product candidates in development: Hedrin, a non-insecticide treatment for pediculosis (head lice); Topical PTH (1-34) for the treatment of psoriasis; Altoderm (topical cromolyn sodium) for the treatment of pruritus associated with dermatologic conditions, including atopic dermatitis, and Altolyn (oral tablet cromolyn sodium) for the treatment of mastocytosis. As of December 31, 2007, Manhattan Pharmaceuticals had not received regulatory approval for, or generated commercial revenues from marketing or selling any drugs. (Source: 10-K)
MOVA Pharmaceutical Corporation is committed to excel as the preferred manufacturing partner of the worldwide research-based pharmaceutical and biotechnology industries. Through its solid strategic alliances and proven performance, MOVA provides manufacturing and development services of the highest quality and greatest cost-effectiveness, as an integral member of each partner's organization. MOVA breathes life into your ideas, working together ... hand in hand. Your success is ours success.
Astellas Pharma Inc is a Japan-based company engaged in the manufacturing and sale of pharmaceuticals and related products. The Company offers its pharmaceuticals to both domestic and overseas markets including Japan, North America, Europe and Asia. In addition, the Company is also engaged in real estate business. The Company has 64 consolidated subsidiaries and three associated companies. (Source: ARS)
Sciele Pharma, Inc. is a pharmaceutical company specializing in sales, marketing and development of branded prescription products focused on the therapeutic areas of Cardiovascular, Diabetes, Women's Health and Pediatrics. The Company's Cardiovascular and Diabetes products treat patients with high cholesterol, hypertension, high triglycerides, unstable angina and Type 2 diabetes; its Women's Health products are designed to improve the health and well-being of women and mothers and their babies; and its Pediatrics products treat allergies, asthma, coughs and colds, and attention deficit and hyperactivity disorder (ADHD). The Company was founded in 1992 and is headquartered in Atlanta, Georgia. The Company employs more than 1,000 people. The Company's success is based on placing the needs of patients first, improving health and quality of life, and implementing its business platform - an Entrepreneurial Spirit, Innovation, Execution Excellence, Simplicity, and Teamwork.
DPT is a contract development and manufacturing organization specializing in semi-solid and liquid dosage forms. Recognized globally for technical expertise and virtually unlimited manufacturing capabilities, DPT is the industry source for fully integrated drug development and manufacturing solutions. At DPT our mission is to improve health and quality of life by providing our healthcare partners the best solutions to their development and manufacturing needs.
Forest Laboratories, Inc. and its subsidiaries develop, manufacture and sell both branded and generic forms of ethical drug products, which require a physician's prescription, as well as non-prescription pharmaceutical products sold over the counter. The Company's products in the United States consist of branded ethical drug specialties marketed directly or detailed to physicians by its sales forces, Forest Pharmaceuticals, Forest Therapeutics, Forest Healthcare, Forest Ethicare and Forest Specialty Sales. Forest Laboratories, Inc.'s products include Lexapro, the Company's selective serotonin reuptake inhibitor (SSRI) for the treatment of major depression and generalized anxiety disorder (GAD); Namenda, its N-methyl-D-aspartate (NMDA) antagonist for the treatment of moderate to severe Alzheimer's disease; Bystolic, its novel beta-blocker for the treatment of hypertension, and Campral, for the maintenance of alcohol abstinence. (Source: 10-K)
Axcan Pharma is a privately-held, leading specialty pharmaceutical company that develops and markets a wide range of products to treat gastrointestinal diseases and disorders, such as inflammatory bowel disease, cholestatic liver diseases, irritable bowel syndrome, and complications related to pancreatic insufficiency. All Axcan's activities underscore the Company's single, well-defined Mission - to improve the quality of care and health of patients suffering from gastrointestinal diseases and disorders by providing effective therapies for patients and their specialized caregivers. Through internal product development and synergistic acquisitions of products and companies, Axcan has built a leadership position in the North American gastroenterology market; just under 85 percent of the Company's business is generated from North American sales. Since Axcan markets its specialized products to a relatively cohesive community of physicians, its sales forces are able to reach this market more easily than pharmaceutical companies with a product portfolio targeting a more diverse range of diseases. Axcan's products are marketed by its own dedicated and specialized sales forces both in North America and the European Union. Axcan Pharma and its global operations are working hand-in-hand to become a multinational leader for disorders linked to gastroenterology. Currently, the Company markets more than 40 products and dosage strengths worldwide in the field of gastroenterology, including several that hold a leading market position. In addition to its marketing activities, Axcan carries out research and development of products at an advanced stage of development that it acquires or licenses from third parties. By combining its marketing expertise with its research and development experience, Axcan distinguishes itself from specialty pharmaceutical companies that focus solely on the distribution of products and offers potential licensors the prospect of rapidly expanding the market for their products. Axcan's unique expertise in its field, combined with its excellent industry reputation and international reach, has enabled the Company to maintain its consistent growth trend and attain its strong market position. Axcan's solid and stable base business provides a platform for the Company to capitalize on its proven business strategy, in order to continue to achieve significant future growth. The Company plans to continue to grow its business by: increasing market penetration and sales of existing products; developing and obtaining marketing approval for new products; in-licensing products and acquiring new products or companies; development of its research and development portfolio, and expanding geographically. Axcan's corporate headquarters are based outside of Montreal, Quebec, Canada. The Company employs almost 500 people worldwide and has additional offices in both the United States and France.
Apotex Inc. was founded in 1974, and is the largest Canadian-owned pharmaceutical company. From its 2 employees, 5,000 square foot beginning, the company has grown to employ over 6,500 people in research, development, manufacturing and distribution facilities world-wide. The Canadian operations of the Apotex Group of Companies with 5,500 employees now occupy over 3.4 million square feet in Montreal, Richmond Hill, Toronto, Etobicoke, Mississauga, Brantford, Windsor, Winnipeg, London, Calgary and Vancouver. Apotex produces more than 300 generic pharmaceuticals in approximately 4,000 dosages and formats which, in Canada, are used to fill over 60 million prescriptions a year - the largest amount of any pharmaceutical company in this country. Today, Apotex is a necessary and trusted member of Canada's healthcare community. The company's pharmaceuticals can be found in virtually every pharmacy and healthcare facility in Canada and are exported to over 115 countries around the globe. Export markets represent an ever growing portion of the total sales. Apotex has also established a presence through subsidiaries, joint ventures or licensing agreements in Australia, Belgium, Czech Republic, Italy, Mexico, Netherlands, New Zealand, Poland, Turkey, and the UK, to name just a few. Healthcare professionals around the world rely on Apotex for quality and value. Although the company's own business is developing and manufacturing generic pharmaceuticals, the success of Apotex has enabled it to diversify into a number of other health-related areas. The Apotex Pharmaceutical Group of Companies also researches, develops, manufactures and distributes fine chemicals, non-prescription and private label medicines, and disposable plastics for medical use. The worldwide sales of the Apotex Group of companies exceed $1 billion (Canadian $) per year.
Cipla Limited is a pharmaceutical company based in India. During the fiscal year ended March 31, 2007 (fiscal 2007), the Company launched many drugs and formulations, which include Ciclohale, which is a steroid inhaler for asthma prophylaxis; SimplyOne, which is a combination therapy for asthma prophylaxis; Neosurf, which is a rescue treatment for neonatal respiratory distress syndrome, and Elcepan, which is a combination therapy for epilepsy. The Company has alliances with nine generic majors including Teva Pharmaceuticals USA, Inc., Watson Pharmaceuticals, Inc., Eon Labs, Inc. and Akorn, Inc. for over 125 projects. It has entered into a research agreement with Avestha Gengraine Technologies Private Limited, to work on a collaborative biopharmaceuticals development programme. The Company has set up a wholly owned subsidiary Cipla FZE, in October 2006, at Jebel Ali Free Zone, Dubai, U.A.E. (Source: ARS)
Elan Corporation, plc (Elan) is a neuroscience-based biotechnology company. Its operations are organized into two business units: Biopharmaceuticals and Elan Drug Technologies (EDT). Biopharmaceuticals engages in research, development and commercial activities primarily areas, such as Alzheimer’s disease, Parkinson’s disease, multiple sclerosis (MS), Crohn’s disease (CD) and severe chronic pain. EDT is a specialty pharmaceutical business unit of Elan. Elan’s marketed products in the the United States include PRIALT (ziconotide intrathecal infusion), AZACTAM (aztreonam for injection, USP) and MAXIPIME (cefepime hydrochloride) for Injection. On June 5, 2006, Elan and Biogen Idec announced the approval of a supplemental Biologics License Application (sBLA) by the United States Food and Drug Administration for the reintroduction of TYSABRI (natalizumab) as a monotherapy treatment for relapsing forms of MS to slow the progression of disability and reduce the frequency of clinical relapses.
Privacy Policy | Terms and Conditions | Do Not Sell My Personal Information | Websites Directory
Copyright © 2022 kwtbox.com. All Rights Reserved. US Business Directory